To evaluate the efficacy of efgartigimod in patients with generalized myasthenia gravis during acute exacerbations.
Multicenter retrospective analysis
Included patients experiencing acute exacerbations
Assessed response to efgartigimod treatment
Efgartigimod showed rapid and significant therapeutic effects
Improvement observed in the majority of patients
Supports its use as a treatment for high-risk individuals
Abstract
Efgartigimod demonstrates rapid, significant efficacy in gMG acute exacerbations/worsening, supporting its role as a valuable therapeutic option for this high-risk population.